We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Apply for changes to your marketing authorisation, including minor variations type IA and IB, major variations type II and extensions.
Lists of products using derogations under the European Commission Directive 2022/642
First published during the 2022 to 2024 Sunak Conservative government
Decision for applicant Accenture Global Services Limited against registration number 15319838, applicant successful.
Neon Healthcare Ltd is recalling the specific batch mentioned in this notification as a precautionary measure.
Submissions related to human medicines need to be submitted directly to the MHRA.
Guidance for the pharmaceutical industry on Marketing Authorisations for veterinary medicines in the UK.
From 13 May 2024 we are introducing a change to the procedure for new Marketing Authorisation (MA) applications, where a joint assessment of labels is requested.
Who in the pharmaceutical industry can be a Marketing Authorisation Holder, named distributor or local representative and how to make changes to these.
Marketing authorisations granted in 2024
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).